drug affinity complex comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Last reviewed on 2026-02-26. Where a claim depends on a specific study, the study is described rather than over-claimed.
Two forms circulate in research settings and are frequently confused. One carries the drug affinity complex and is often written as CJC-1295 with DAC; the other lacks that group and is usually called modified GRF(1-29). The two share the same core sequence but differ sharply in how long they persist in blood. Products labelled only as CJC-1295 normally refer to the version carrying the complex. Documentation that omits the distinction leaves the intended molecule ambiguous.
CJC-1295 is a synthetic peptide built as a long-acting analogue of growth hormone-releasing hormone. Its backbone matches the first twenty-nine residues of the natural human hormone, with four amino acid substitutions added to slow enzymatic breakdown. A reactive maleimide group, commonly termed the drug affinity complex, allows the peptide to attach to circulating albumin after administration. That albumin attachment keeps the molecule in the bloodstream for an extended period instead of being cleared within minutes.
Naming in this area is inconsistent, and readers should treat product labels with care. In much of the literature and in vendor catalogs, the unqualified term refers to the albumin-binding version, while the version lacking the DAC group appears as modified GRF(1-29), mod GRF(1-29), or the same name with a without-DAC qualifier. Because one abbreviation has been applied to both materials, the only reliable way to identify a sample is to check the stated sequence and the presence of the linker.
CJC-1295 is the name used for a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound was described by a Canadian drug discovery company in the mid-2000s as a long-acting research tool. Two closely related molecules share the name in practice: one carries a drug affinity complex, or DAC, group, and one does not. The distinction matters because the two behave differently in circulation.
| Property | Value | Notes |
|---|---|---|
| Molecular formula | C152H252N44O42 | Cited for the form without the drug affinity complex |
| Molecular weight | About 3368 Da | Reported value for modified GRF(1-29) |
| Appearance | White to off-white powder | Lyophilised solid as usually supplied |
| Solubility | Soluble in water and polar solvents | Clarity depends on purity and salt content |
| Typical storage | -20 C or below, dry | Protect from light and repeated warming cycles |
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Four amino acid substitutions separate the modified backbone from the parent GRF(1-29) sequence. These changes reduce recognition by dipeptidyl peptidase IV and related proteases, extending the interval before degradation. Development work in this area sought longer-acting GHRH analogs for endocrine investigation. Published descriptions treat the substitution set as a defining property of the core sequence, while the albumin-binding linker is described separately as an optional addition to that same backbone.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
The core sequence keeps the receptor-binding region of GHRH while replacing four positions that are vulnerable to dipeptidyl peptidase-4 and other proteases. Substitutions at positions 2, 8, 15, and 27 raise metabolic stability relative to the natural hormone. The N-terminal residues remain essential for activity, so changes there generally lower potency. Molecular weight sits near 3368 daltons for the tetrasubstituted analog without the linker, while the albumin-binding form is heavier because of the added maleimide group.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
Purity is most often assessed by reversed-phase high-performance liquid chromatography, reported as a percentage of total peak area. Identity is confirmed by mass spectrometry, which yields a molecular ion consistent with the expected sequence. Amino acid analysis and peptide mapping provide additional characterization. Reported purity values are method-dependent, so figures from different laboratories are not always directly comparable without details of column, gradient, and detection wavelength.
Peptide degradation proceeds mainly through hydrolysis, oxidation of methionine, and deamidation of asparagine or glutamine residues. The maleimide group on the albumin-binding variant can also react with thiols or hydrolyze in aqueous media. Because these pathways accelerate with temperature and pH extremes, handling conditions strongly influence measured stability. Stability data in the public literature are limited and often generated under differing conditions, so general statements about shelf life should be read as approximate.
Research material is normally supplied as a freeze-dried powder in sealed vials. In that state the peptide is comparatively robust, but prolonged exposure to warmth, moisture, or light accelerates degradation. Storage at minus twenty degrees Celsius or lower, with desiccant and protection from light, is the commonly described practice. Vials should be allowed to reach room temperature before opening to limit condensation on the powder. Moisture uptake during handling is a recognized source of variability in later measurements.
== Research == Stanozolol has been investigated in the treatment of a number of dermatological conditions including urticaria, hereditary angioedema, Raynaud's phenomenon, cryofibrinogenemia, and lipodermatosclerosis.
27 February A PAVN rocket hit LCU-1500 while it was loading at the Bridge Ramp in Da Nang killing 13 crewmen. In Paris the U.S. stated that the Tet 69 attacks, particularly against civilian targets, breached the understanding behind the bombing halt.
=== Chemical handles === Chemical handles are used to detect post-translationally modified proteins. Recently, there is a N6pATP that contains an alkynyl tag (propargyl) at the N6 position of the adenine of ATP. This N6pATP combines with the click reaction to detect AMPylated proteins. To detect unrecognized modified protein and label VopS substrates, ATP derivatives with a fluorophore at the adenine N6 NH2 is utilized to do that.
== Medical uses == Mineralocorticoid receptor antagonists are diuretic drugs that work primarily on the kidneys. They decrease sodium reabsorption, which leads to increased water excretion by the kidneys. By regulating water excretion, mineralocorticoid receptor antagonists lower blood pressure and reduce fluid around the heart which can be very beneficial in some cardiovascular conditions. Mineralocorticoid receptor antagonists have been used for many clinical conditions in the cardiovascular system. It has proven beneficial for diseases like primary aldosteronism, primary and resistant hypertension, heart failure and chronic kidney disease. They are often used with other medications, such as ACE inhibitors or beta blockers.
== Current research == In her Yale laboratory, Horsley has studied the cellular and molecular pathways involved in skin tissue development and maintenance, as well as the relationship between fat cells in the skin, wound healing, regeneration of hair follicles, and the formation of keratinocytes during embryonic development. Horsley currently studies adult stem cells in epithelial skin tissue and how these cells contribute to wound healing and the development of cancer, using the mouse as a genetic model system. Horsley revolutionized the field of epithelial stem cell biology by identifying skin adipocyte stem cells, establishing a major role for these progenitor cells in regulating turnover, rejuvenation and wound repair of the skin epidermis and hair follicles. She found that within epithelial tissues, cells tend to confine to distinct micro-environments. Mechanisms of adipocyte cells in tissue homeostasis and regeneration are not well understood. Horsley discovered the source of both fat cells and immune cells as local signals, as the hormone signal, prolactin, is responsible for stem cell activity and the regeneration of skin cells. Together, her laboratory also found that cell differentiation of adipocytes and hair growth occur simultaneously, and when the cell differentiation process (adipogenesis) ceases, hair growth stops and the follicles deteriorate. Her team identified specific adipose progenitors in the skin, which indicated the necessity of these cells to sufficiently induce hair follicle growth.
Sources: en.wikipedia.org
After one round of selection of an alpha-L-threofuranosyl nucleic acid (TNA) polymerase, they demonstrated roughly 14-fold improvement in activity and >99% correct placement of residues in a growing polypeptide. In 2017, S. S. Terekhov et al. developed monodisperse microfluidic double water-in-oil-in-water emulsion (MDE) sorting, which they combined with FACS followed by liquid chromatography-mass spectrometry (LC-MS) and next-generation sequencing (NGS). The authors demonstrated high sensitivity sorting of enzymatically active yeast cells from non-active cells using fluorescence. Further, they showed the ability of their MDE-FACS system to interrogate interactions between target and effector cells within droplets without interference from other yeast and bacterial cells. Rather than developing new platforms, some groups have focused on the optimization of existing methods, tools and platforms to simplify and improve their ease of use by non-experts. In 2017, Sukovitch et al.created a system to produce monodisperse or approximately equal size DEs by cutting out the coating process required for DE chips. Various groups have altered surfactant types and concentrations to simplify reagent delivery in SEs and DEs. In 2018, Ma et al. presented a dual-channel microfluidic droplet screening system (DMDS). The system uses fluorogenic tags to sort SEs by two different properties of a target enzyme at the same time. Using DMDS, Ma and coworkers directed the evolution of a highly enantioselective esterase using multiple enzymatic properties. In 2020, Brower et al.
This off-gassing has a multi-exponential decay trend that is discernible over at least two years, with the most volatile compounds decaying with a time-constant of a few days, and the least volatile compounds decaying with a time-constant of a few years. New buildings may require intensive ventilation for the first few months, or a bake-out treatment. Existing buildings may be replenished with new VOC sources, such as new furniture, consumer products, and redecoration of indoor surfaces, all of which lead to a continuous background emission of TVOCs, and requiring improved ventilation. There are strong seasonal variations in indoors VOC emissions, with emission rates increasing in summer. This is largely due to the rate of diffusion of VOC species through materials to the surface, increasing with temperature. This leads to generally higher concentrations of TVOCs indoors in summer.
Materials science is a highly active area of research. Together with materials science departments, physics, chemistry, and many engineering departments are involved in materials research. Materials research covers a broad range of topics; the following non-exhaustive list highlights a few important research areas.
== External links == The Accreditation Council for Graduate Medical Education in the United States The American Osteopathic Association Accreditation for osteopathic residency Educational Commission for Foreign Medical Graduates Robert N. Wilkey, Federal Whistleblower Protection: A Means to Enforcing Maximum Hour Legislation for Medical Residents, William Mitchell Law Review, Vol. 30, Issue 1 (2003)
Opioid effects (adverse or otherwise) can be reversed with an opioid antagonist such as naloxone or naltrexone. These competitive antagonists bind to the opioid receptors with higher affinity than agonists but do not activate the receptors. This displaces the agonist, attenuating or reversing the agonist effects. However, the elimination half-life of naloxone can be shorter than that of the opioid itself, so repeat dosing or continuous infusion may be required, or a longer acting antagonist such as nalmefene may be used. In patients taking opioids regularly who receive opioid antagonists under medical supervision, it is essential that the opioid is only partially reversed to avoid a severe and distressing reaction of waking in excruciating pain. This is achieved by not giving a full dose but giving this in small doses until the respiratory rate has improved. An infusion is then started to keep the reversal at that level, while maintaining pain relief. Opioid antagonists remain the standard treatment for respiratory depression following opioid overdose, with naloxone being by far the most commonly used, although the longer acting antagonist nalmefene may be used for treating overdoses of long-acting opioids such as methadone, and diprenorphine is used for reversing the effects of extremely potent opioids used in veterinary medicine such as etorphine and carfentanil.
Sources: en.wikipedia.org
=== Other formulations === The original oral formulation of selegiline was developed for the treatment of depression. However, it ended up being developed and approved for the treatment of Parkinson's disease instead. In any case, oral selegiline has been widely used off-label to treat depression. The transdermal patch form of selegiline was developed and approved specifically for the treatment of depression. It was also under development for the treatment of Alzheimer's disease, attention deficit hyperactivity disorder (ADHD), cognition disorders, and Parkinson's disease, but development for these indications was discontinued. The ODT form of selegiline was developed and licensed exclusively for the treatment of Parkinson's disease.
Foreign versions of Lipitor and Celebrex were smuggled into the U.S. from South America and resold after being repackaged to conceal the true origin of the drugs. Counterfeit Lipitor was manufactured in South America and smuggled into the US, where it sold after commingling with the genuine foreign Lipitor. Participants conspired to buy, sell and traffic almost eight million dollars' worth of stolen Glaxo Smith Kline and Roche drugs, using fake pedigrees to launder the drugs and thereby concealing that they were stolen. There also were charges related to the sale of counterfeit Procrit, as well as counterfeit and misbranded Serostim and Neupogen. Procrit is an injectable drug used in the treatment of anemia, Serostim is Serono's brand name form of synthetic somatropin (i.e. human growth hormone formed using laboratory methods of genetic recombination) marketed for HIV-associated wasting, and Neupogen is an injectable drug used by cancer patients to stimulate the production of white blood cells in order to decrease the incidence of infections. In 2005, the FDA held a Congressional hearing to review the situation. The U.S. is an especially attractive market for counterfeiters, because 40% of worldwide annual prescription drug sales were made in the United States in 2007. In 2011, a "PROTECT IP Act" was proposed to deter advertising. Between 2002 and 2010, drug imports to the U.S. more than doubled, with 80% of drugs' active ingredients imported, now accounting for 40% of finished medicines. In 2015, the U.S.
==== Redox reactions ==== Redox reactions are prevalent for the transition elements. Two classes of redox reaction are considered: atom-transfer reactions, such as oxidative addition/reductive elimination, and electron-transfer. A fundamental redox reaction is "self-exchange", which involves the degenerate reaction between an oxidant and a reductant. For example, permanganate and its one-electron reduced relative manganate exchange one electron:
Police confirm that the remains of two men were found in suitcases at Clifton Suspension Bridge, Bristol, while a separate crime scene is opened in London. Justice Secretary Shabana Mahmood confirms that thousands of prisoners in England and Wales will be released early from their sentences at the beginning of September, warning of the "total collapse" of the prison system and a "total breakdown of law and order" without steps being taken to ease prison overcrowding. NHS England announces that patients with multiple sclerosis in England, Wales and Northern Ireland will be offered injections of ocrelizumab, which can slow the progress of the disease. Princess Anne returns to public duties following treatment for a head injury. 13 July A 34-year-old man is arrested at Bristol's Temple Meads railway station on suspicion of murder following the discovery of human remains in two suitcases at Clifton Suspension Bridge. Energy Secretary Ed Miliband approves the Gate Burton, Sunnica, and Mallard Pass solar farms, totalling 1.3 gigawatts of new capacity, as Labour announces a "rooftop revolution" to boost home installations of solar power. Researchers have discovered the great silver water beetle in the UK for the first time in 86 years after one was found at the Great Fen in Cambridgeshire. 2024 Wimbledon Championships: Barbora Krejcikova wins the Women's singles final. Great Britain's Henry Patten and Finland's Harri Heliovaara win the Men's doubles. Buckingham Palace confirms that the Princess of Wales will attend the Men's singles final.
Certain other inherited diseases are associated with an increased risk of developing soft-tissue sarcomas. For example, people with neurofibromatosis type I (also called von Recklinghausen disease, associated with alterations in the NF1 gene) are at an increased risk of developing soft-tissue sarcomas known as malignant peripheral nerve-sheath tumors. Patients with inherited retinoblastoma have alterations in the RB1 gene, a tumor-suppressor gene, and are likely to develop soft-tissue sarcomas as they mature into adulthood.
Sources: en.wikipedia.org
It is a synthetic peptide analogue of growth hormone-releasing hormone. Four substitutions in its sequence make it more resistant to enzymatic degradation than the natural hormone. In the version carrying a drug affinity complex, the peptide binds albumin and remains in circulation for days.
No regulatory agency has approved CJC-1295 for clinical use. Human trials were conducted in the 2000s, but the development programme was discontinued before any marketing application succeeded. Material sold today is offered as a research chemical, and its purity depends on the supplier.
Sermorelin is an unmodified fragment of growth hormone-releasing hormone and is cleared quickly. CJC-1295 contains substitutions that resist breakdown, and the form with a drug affinity complex persists much longer. Both act at the same receptor but differ substantially in duration of action.
No. It is a laboratory-made analog of growth hormone-releasing hormone. The natural hormone is a 44-residue peptide, while the analog is built on a shorter 29-residue fragment.